However, GKT136901 was found to scavenge peroxynitrite, which may complicate the interpretation of results from NOX-inhibitory assays (GKT137831 does not scavenge RS)
The market is being reshaped by 6 forces: Market size: $94B today $216B+ by 2035 (8.8% CAGR) Oral GLP-1s just got FDA approval eliminating the needle barrier for millions WHO officially recommends GLP-1s for long-term obesity treatment (Dec 2025) Novo Nordisk slashed Ozempic/Wegovy prices by up to 70% unlocking mass adoption Next-gen tri-agonists (retatrutide) showing 28.7% weight loss in trials Only ~7% diabetes penetration and ~2% obesity penetration the growth runway is massive The ripple effects extend far beyond pharma: Food & beverage: $30$55B annual revenue at risk as GLP-1 users cut calories by 21% Employers: 77% of large companies say managing GLP-1 costs is a top priority Eli Lilly became the first pharma company to surpass $1 trillion market cap ~150 GLP-1 drugs now in development globally 2530 million Americans projected on GLP-1 therapy by 2030 The question isnt whether GLP-1s will reshape global healthcare
With the shortage officially resolved, that allowance is being phased out
Talk to a doctor about whether your Ozempic dose needs adjustment or if an alternative GLP-1 might work better for you
Its precision and minimal off-target activity make it an ideal candidate for studies involving endocrine regulation, muscle wasting, and recovery support
Food and Drug Administration (FDA) approval Egrifta, cleared in 2010 for one specific indication, reduction of excess visceral fat in HIV-associated lipodystrophy
